Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KRYSTAL BIOTECH, INC.

(KRYS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
57(c) 58.33(c) 59.85(c) 58.44(c) 57.89(c) Last
133 352 212 273 129 320 75 889 98 095 Volume
-0.66% +2.33% +2.61% -2.36% -0.94% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -86,9 M - -
Net cash position 2021 346 M - -
P/E ratio 2021 -15,6x
Yield 2021 -
Sales 2022 333 M - -
Net income 2022 -80,5 M - -
Net cash position 2022 281 M - -
P/E ratio 2022 -18,0x
Yield 2022 -
Capitalization 1 285 M 1 285 M -
EV / Sales 2021 -
EV / Sales 2022 3,01x
Nbr of Employees 75
Free-Float 75,4%
More Financials
Company
Krystal Biotech, Inc. is a clinical-stage gene therapy company. The Company is using its proprietary Skin TARgeted Delivery (STAR-D) platform to develop treatments for skin diseases. The CompanyÔÇÖs products are directed to the treatment of monogenic and congenital skin diseases, including dystrophic epidermolysis bullosa (DEB) and autosomal recessive congenital ichthyosis (ARCI). DEB is an incurable, often fatal... 
More about the company
Ratings of Krystal Biotech, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about KRYSTAL BIOTECH, INC.
08/02KRYSTAL BIOTECH, INC. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
07/21NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
07/20KRYSTAL BIOTECH : Goldman Sachs Lifts Krystal Biotech to Buy From Neutral, Price..
MT
07/07KRYSTAL BIOTECH, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
07/01KRYSTAL BIOTECH : Provides Update on the Clinical Trial Evaluating Topical KB105..
PU
07/01KRYSTAL BIOTECH, INC. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
07/01KRYSTAL BIOTECH : Reports Updated Data for Prospective Treatment of TGM-1 Associ..
MT
07/01Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB10..
GL
07/01Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB10..
CI
06/25KRYSTAL BIOTECH, INC.(NASDAQGM : KRYS) added to Russell Small Cap Comp Value Ind..
CI
06/25KRYSTAL BIOTECH, INC.(NASDAQGM : KRYS) added to Russell 3000E Value Index
CI
06/25KRYSTAL BIOTECH, INC.(NASDAQGM : KRYS) added to Russell 2000 Value Index
CI
06/25KRYSTAL BIOTECH, INC.(NASDAQGM : KRYS) added to Russell 3000 Value Index
CI
06/25KRYSTAL BIOTECH, INC.(NASDAQGM : KRYS) added to Russell 2500 Value Index
CI
06/03KRYSTAL BIOTECH : to Participate in Upcoming Investor Conferences
AQ
More news
News in other languages on KRYSTAL BIOTECH, INC.

- No features available -

More news
Analyst Recommendations on KRYSTAL BIOTECH, INC.
More recommendations
Chart KRYSTAL BIOTECH, INC.
Duration : Period :
Krystal Biotech, Inc. Technical Analysis Chart | KRYS | US5011471027 | MarketScreener
Technical analysis trends KRYSTAL BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 57,89 $
Average target price 102,13 $
Spread / Average Target 76,4%
EPS Revisions
Managers and Directors
Krish S. Krishnan Chairman, President & Chief Executive Officer
George Chen Manager-Information Technology & CSV
Trevor Parry Director-IP & Scientific Affairs
Brittani Agostini Manager-Clinical Operations
Court Freedman Senior Scientist
Sector and Competitors
1st jan.Capi. (M$)
KRYSTAL BIOTECH, INC.-3.52%1 285
GILEAD SCIENCES, INC.17.22%85 648
BIONTECH SE317.33%79 303
WUXI APPTEC CO., LTD.36.10%59 516
REGENERON PHARMACEUTICALS18.94%59 505
VERTEX PHARMACEUTICALS-16.09%52 296